期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

EGFRI皮肤毒性的发生机制和处理策略 被引量：17

Mechanism and management of cutaneous toxicities associated with epidermal growth factor receptor inhibitors
在线阅读 下载PDF
导出
摘要 表皮生长因子受体抑制剂已在肿瘤治疗中显示重要作用,皮肤毒性是该类药物最常见的不良反应之一,本文就该类药物治疗相关性皮肤毒性的发病情况、临床表现特点、发生机制和处理对策等作一综述。 Inhibitors of epidermal growth factor receptor have played an importment roles part in the treatment of tumor. The most common adverse effects are cutaneous toxicities. The article reviews the incidence, clinical manifestation, mechanism and management for acneform eruption which related to inhibitors of epidermal growth factor receptor.
作者 钱军 李慧 秦叔逵
机构地区 解放军
出处 《现代肿瘤医学》 CAS 2009年第6期1186-1191,共6页 Journal of Modern Oncology
关键词 表皮生长因子受体抑制剂 皮肤毒性 不良反应 inhibitors of epidermal growth factor receptor cutaneous toxicities adverse effects
分类号 R730.54 [医药卫生—肿瘤]
  • 相关文献

参考文献39

  • 1钱军,秦叔逵.针对表皮生长因子受体的靶向治疗研究进展[J].中国药科大学学报,2004,35(3):285-288. 被引量：14
  • 2Mendelsohn J,Baselga J.Epidermal growth factor receptor targeting in cancer[J].Semin Oncol,2006,33(4):369-385.
  • 3Arteaga CL.The epidermal growth factor receptor:From mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia[J].J Clin Oncol,2001,19(suppl 18):32S-40S.
  • 4Fox LP.Nail toxicity associated with epidermal growth factor receptor inhibitor therapy[J].J Am Acad Dermatol,2007,56(3):460-465.
  • 5Lenz HJ.Anti-EGFR mechanism of action:antitumor effect and underlying cause of adverse events[J].Oncology,2006,20(5suppl 2):5-13.
  • 6Lynch TJ,Kim ES,Eaby B,et al.Epidemal growth factor receptor inhibitor-associated cutaneous toxicities:an evolving paradigm in clinical management[J].Oncologist,2007,12(5):610-621.
  • 7Giaccone G,Herbst RS,Manegold C,et al.Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer:a phase Ⅲ trial-INTACT1[J].J Clin Oncol,2004,22(5):777-784.
  • 8Johnson JR,Cohen M,Sridhara R,et al.Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen[J].Clin Cancer Res,2005,11(18):6414-6421.
  • 9Wacker B,Nagrani T,Weinberg J,et al.Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies[J].Clin Cancer Res,2007,13(13):3913-3921.
  • 10Giusti RM,Shastri KA,Cohen MH,et al.FDA drug approval summary:Panitumumab(VectibixTM)[J].Oncologist,2007,12(5):577-583.

二级参考文献18

  • 1Yarden Y.The EGFR family and its ligands in human cancer.Signaling mechanisms and therapeutic opportunities[J].Eur J Cancer,2001,37(Suppl 4):3-8.
  • 2Baselga J.The EGFR as a target for anticancer therapy-focus on cetuximab[J].Eur J Cancer,2001,37(1):16-22.
  • 3Shin DM,Donato Nj,Perez SR,et al.Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer[J].Clin Cancer Res,2001,7(9):1204-1213.
  • 4Hollywood E.Clinical issues in the administration of an anti-epidermal growth factor receptor monoclonal antibody,IMC-C225[J].Semin Oncol Nurs,2002,18(2 Suppl 2):30-35.
  • 5Yang XD,Jia XC,Corvalan JR,et al.Development of ABX-EGF,a fully human anti-EGF receptor monoclonal antibody,for cancer therapy[J].Crit Rev Oncol Hematol,2001,38(1):17-23.
  • 6Bclselga J.Clinical trial of signle-agent Trastuzumab(Herceptin) [J].Semin Oncol,2000,27(5 Suppl 9):20-26.
  • 7Fornier M,Esteva FJ,Seidman AD.Trastuzumab in combination with chemotherapy for treatment of metastatic breast cancer[J].Semin Oncol,2000,27(6 Suppl 11):38-45.
  • 8Kate MK,Caroline MP.Trastuzumab:A review of its use in the treatment of metastatic breast cancer overexpresseing HER-2[J].Drugs,2002,62(1):209-243.
  • 9Gonzalez B,Casaco A,Alvarez P,et al.Radiotoxicity of h-R3 monoclonal antibody labled with 188Re administered intracerebrally in rats[J].Hum Exp Toxicol,2000,19(6):684-692.
  • 10Bier H,Hoffmann T,Hauser U,et al.Clinical trial with escalating doses of the antiepidermal growth factor receptor humanized monoclonal antibody EMD72000 in patients with advanced squamous cell carcinoma of the larynx and hypopharynx[J].Cancer Chemother Pharmacol,2001,47(6):519-524.

共引文献13

同被引文献147

引证文献17

二级引证文献94

现代肿瘤医学
2009年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部